A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state
- PMID: 3731204
- PMCID: PMC11038367
- DOI: 10.1007/BF00200032
A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state
Abstract
Studies were performed on the activation of human blood monocytes to the antitumor state by a dried preparation of multilamellar vesicle (MLV) liposomes in which synthetic muramyl tripeptide phosphatidylethanolamine (MTP-PE) was inserted directly into the liposome membrane. Dried liposomes composed of synthetic phospholipids [phosphatidylcholine (PC) and phosphatidylserine (PS) in a molar ratio of 7:3] were prepared by lyophilization. Dried liposome-MTP-PE was found to be superior in several ways to free desmethyl muramyl dipeptide (norMDP) or conventional liposome-MTP-PE, prepared immediately before use. First, dried liposome-MTP-PE was stable and strongly activated monocytes when stored for over 3 months in a freezer at -20 degrees C or even in suspension at 4 degrees C. Second, human monocytes in suspension, as well as in the adherent form, were activated to the tumoricidal state by interaction for at least 4 h with the dried preparation of liposome-MTP-PE. Third, monocytes activated with the dried liposome-MTP-PE or conventionally prepared liposome-MTP-PE maintained their tumoricidal activity for a longer period (4 days) than those activated with free norMDP. These results indicate that the dried preparation of liposome-MTP-PE can be stored for a long time, has a reproducible effect that can be standardized and should be valuable for in situ activation of human monocytes to the tumoricidal state, which is associated with eradication of cancer metastases.
Similar articles
-
Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.Cancer Res. 1986 Oct;46(10):5039-44. Cancer Res. 1986. PMID: 3489519
-
Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.Int J Immunopharmacol. 1987;9(2):141-50. doi: 10.1016/0192-0561(87)90088-9. Int J Immunopharmacol. 1987. PMID: 3583507
-
Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.Cancer Commun. 1991;3(10-11):313-21. doi: 10.3727/095535491820873740. Cancer Commun. 1991. PMID: 1722107
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Hematol Oncol Clin North Am. 1995. PMID: 7490249 Review.
-
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.Cancer Treat Res. 1993;62:101-7. doi: 10.1007/978-1-4615-3518-8_14. Cancer Treat Res. 1993. PMID: 8096724 Review.
Cited by
-
Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat.Clin Exp Metastasis. 1995 Sep;13(5):328-36. doi: 10.1007/BF00121909. Clin Exp Metastasis. 1995. PMID: 7641418
-
Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.Cancer Immunol Immunother. 1991;33(5):285-92. doi: 10.1007/BF01756592. Cancer Immunol Immunother. 1991. PMID: 1868486 Free PMC article.
-
In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362.Cancer Immunol Immunother. 1991;33(6):375-81. doi: 10.1007/BF01741597. Cancer Immunol Immunother. 1991. PMID: 1878891 Free PMC article.
-
Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.Br J Cancer. 1991 Mar;63(3):399-403. doi: 10.1038/bjc.1991.92. Br J Cancer. 1991. PMID: 2003980 Free PMC article.
-
A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives.Molecules. 2022 Feb 17;27(4):1372. doi: 10.3390/molecules27041372. Molecules. 2022. PMID: 35209162 Free PMC article. Review.
References
-
- Deodhar SD, James K, Chiang T, Edinger M, Barna BP. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res. 1982;42:5084. - PubMed
-
- Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G. The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res. 1980;140:4460. - PubMed
-
- Fidler IJ, Raz A, Fogler WE, Hoyer LC, Poste G. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. Cancer Res. 1981;41:495. - PubMed
-
- Fidler IJ, Sone S, Fogler WE, Smith D, Braun DG, Tarcsay V, Gisler RH, Schroit AJ. Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J Biol Response Mod. 1982;1:43.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources